

Index

- Acetylcholine, 80, 112, 118
 in brain, 129-132
 and excitation, 129-134
 mechanism of action, 134, 135
- Acetylcholinesterase, 131
- Acquisition, 12
- Alcoholics, 61-75
 fixed ratio cost of drinks, 66
 loss of ward privileges, 66, 70; 72
 spacing, temporal, 68
 token economy procedure, 73
- Amantadine, 267
- Amine, biogenic, 96; *see also* Neurotransmitter
 and individual amines
- Amphetamine, 5, 7, 15-22, 25, 92, 97, 99, 101-
 108, 139, 148, 149, 230, 231, 234-236,
 240-244, 251-259, 267-269, 271, 273
 abuse, 182-184
 as central nervous system stimulant, 182
 as decongestant (1932), 182
 dependence, 184
 first synthesized (1887), 182
 overdose, 183
 psychosis, human, 184
 speed freak, 184
 toxicity, 157, 181-194
 behavioral index, 181-194
 lethal, 226
 neuropathological index, 181-194
- Angiitis, necrotizing, 182
- Antagonist, narcotic, 45-60
 avoidance, 53-56
 behavioral effect, 46-49, 58
 escape, 53-56
 negative reinforcer, 53
 response-eliciting function, 46
- Antianxiety agents, 269-281
 conflict model, 269-271, 275-278
- Anticholinergics and behavior, 79, 80
- Antidepressant, 268, 269
- Apomorphine, 140, 267
- Approach behavior, 117-136
- Aramine, *see* Metaraminol
- Asbestos, 157
 consequences, behavioral, 158
 consequences, neurological, 158
 and mesothelioma, 155
 poisoning, 157
- Aspirin, 195
 and arthritis, 196
 and deafness due to, 196, 197
- Astereognosis, 220
- Atropine, 131-133, 267
 action, 132
 alkaloid, 132
 methyl-, 132, 133
- Autophagosome, 174
- Avoidance
 behavior, 78, 117-136
 conditioned, 141, 267
 blocking potency, 267
 discrete, 267
 escape responding, 56
 nonoccurrence, 53-56
 responding, 129
 Sidman shock-avoidance schedule, 129, 267
- B-cell system, 175
- Barbiturate, 230, 231, 242, 244, 271; *see also*
 individual compounds
- Baseline rate of responding, defined, 138
- Beagle, dark adaptation, *see* Dog
- Behavior
 acquisition, 12
 approach-, 117-136
 avoidance-, 78, 117-136
 biochemical pharmacology of, 80
 and biogenic amine, 96, 97
 and catecholamine, 80, 137-153
 conditioned, 96, 97
 depression, 96, 129
 deprivation, 139
 discriminating, 45, 46
 disruption by cholinergic mechanism, 117-
 136
 disruption by serotonergic mechanism, 117-
 136
 —drug interaction, 137-153
 and catecholamine, 137-153
 drug-reinforced, 13; *see also* Reinforcement
 eliciting, 45, 46
 eliminating drug control, 12
 escape-, 78
 excitation, 129
 extinction, 25
 inhibition, 129

- Behavior (*cont.*)
 maintenance, 12
 method, choice of, 97-113
 and neurochemistry, 77-81, 95-115
 ongoing and drugs, 226
 operant, 138
 analysis, 96
 rate-dependent, 139
 punishment, 45, 46, 49-53
 as quasimythical concept, 79
 reducing drug control, 12
 reinforcing, 45, 46, 139, 227
 repetitive, 186
 schedule-controlled, 95-115, 225-227
 as determinant of drug response, 225-227
 Skinner's work, 156, 276
 stereotypical, 186
 stimulus, 45, 46
- Behavioral pharmacology, 78, 79, 156
 biochemical, 80
 explicit, 79
 future of, 1, 2
 implicit, 79
 reinforcement, *see* Reinforcement
 toxicology, *see* Behavioral toxicology
- Behavioral toxicology, 155-164
 clinical aspects, 157-159
 compared with pharmacology, 156, 157
- Benactyzine, 231
- Benzodiazepine, 230-232, 242, 244, 271, 273, 277, 278
- Bernard, Claude, 4
- Biochemical pharmacology of behavior, 80
- Brain chemistry
 and behavior, 138
 and drugs, 138
 and environment, 138
- Brain dysfunction, minimal, 158
- Brucella abortus* antigen, 175
- Caffeine, 79, 231
- Carbamic acid ester, 271
- Carbon disulfide, consequences
 behavioral, 158
 neurological, 158
- Carbon monoxide, consequences
 behavioral, 158
 neurological, 158
- Cat, 38, 244
- Catalepsy, 267, 268
- Catecholamine, 143
 and behavior, 80, 137-153
 —drug interaction, 137-153
 maintenance, 141
 and depression, 150
- Catecholamine (*cont.*)
 drug—behavior interaction, 137-153
 and environment, 143-150
 and hyperkinesis, 150
 metabolism, 139, 143-150
 and motor activity, 151
 as transmitter in central nervous system, 138
- Catechol-O-methyltransferase inhibitor, 140
- Chimpanzee, 38
- Chloral hydrate, 231
- Chlordiazepoxide, 15, 232-234, 238, 269, 271-280
- DL-*p*-Chlorophenylalanine, 86, 277-280
- Chlorpromazine, 15, 16, 24, 77-79, 92, 140, 226, 230, 231, 240, 241, 252, 254, 256, 259, 267, 269-273
- Chlorprothixene, 267
- Choline acetyltransferase, 174, 175
- Cholinesterase, 174, 175
- Clonidine, 140
- Clozapine, 268
- Cocaine, 16, 17, 20-24, 37-43, 139, 268-269
 fixed-interval schedule, 37, 38
 fixed-ratio schedule, 37-40
 and green light, 37
- Codeine, 47, 48
 recovery, 51
 reinforced responding, 49-53
- Color blindness, 199, 200
- Community Mental Health Movement, 78
- Conditioned emotional response procedure (CER), 280, 281
- Conditioned fear, *see* Fear
- Conditioned suppression, *see* Suppression
- Conflict model, 269-271, 275-278
- Deafness, due to
 aspirin, 196, 197
 kanamycin, 196, 198
 streptomycin, 195
- Deficiency
 immunological, 170, 174
 neuromuscular, 170, 174
- Depression, mental, 96, 129, 135, 182, 199
- Desmethylinipramine, 99
- Development, organismal
 and chemical at low levels, 161-180
 behavioral effects, 161-180
 latent effects, 161-180
 deviation, behavioral, 169
 evaluation criteria
 activity level, 165, 166
 emotionality, 165, 166
 growth, 165, 166
 learning ability, 165, 166

- Development, organismal (*cont.*)
 evaluation criteria (*cont.*)
 maturational, 165, 166
 morphological, 165, 166
 neuromuscular, 165, 166
 physical, 165, 166
 reflex, 165, 166
 response, 165, 166
 sensory-motor capacity, 165, 166
 sexual, 165, 166
 research strategy
 cross-sectional, 164
 longitudinal, 164-166
 vulnerability during, 162-167
- Deviation, behavioral, during development
 open-field test, 169
 swimming test, 169
see Methylmercury
- Diazepam, 233, 238-240, 271, 276, 277
- L-Dihydroxyphenylalanine, 141
- Diphenylhydantoin, 231
- Disulfiram, 30, 140
- Dog
 bleaching of tapidum lucidum, 200
 dark adaptation of beagle, 200, 201
- L-Dopa, 141, 267
- Dopa decarboxylase, 141, 143, 144
- Dopamine, 85, 87, 96, 112, 120, 123, 126, 139-142, 148, 190, 192
 and neuroleptics, 266-268
 receptor blockade hypothesis, 267
- Dopamine β -hydroxylase inhibitor, 140
- Dose of drug, 4, 5
- Drug
 abuse, 4
 acquisition, 12-18
 action
 discrete trial analysis, 283-294
 modulation by discriminative stimuli, 249-264
 operant technique, 283-284
 response rate, 284
 behavioral effect, 11-37, 266
 behavioral interaction, 137-153
 conditioning, 6, 7
 control
 eliminating, 12
 reducing, 12
 dependence, 11-33
 behavioral factors, 11-37
 dose, 4-5
 effect and punished responding, 229-247
 elimination, 22-26
 and environment, 266
 implication for humans, 26-30
 maintenance, 18-22
- Drug (*cont.*)
 as reinforcer, *see* Reinforcement
 response, 45-60
 schedule-controlled behavior, 225-227
 as reward, 12
 "rush," 5
 schedule, 5, 6, 20
 fixed-ratio, 20
 variable-interval, 20
 variable-ratio, 20
 self-administration, human, 61-75
 ethanol by alcoholics, 61-75
 models for modifying, 61-75
 self-injection by animal, 4-9
 external environmental factors, 4-7
 conditioning, 6, 7
 dose, 4, 5
 schedule, 5, 6
 fixed-interval schedule, 36, 39
 fixed-ratio schedule, 36, 39
 history, 4
 internal environmental factors, 7
 as reinforcer to maintain operant behavior, 36
 second-order schedule, 39-43
 simple schedule, 36-39
 tolerance, 244
 toxicity evaluation, 181
 animal model, 182
 voluntary intake, 3-9
 and environmental influences, 3-9
- Edema, cerebral, 183
- Erylcamate, 231
- Environment
 external factors, 4-7
 internal factors, 7
 and voluntary drug intake, 3-9
- Epinephrine and blood pressure, 266
- Escape
 avoidance responding, 56
 response-contingent termination, 53-56
- Ethacrynic acid, 195
- Ethanol, 17, 18, 20, 23, 231
 abstinence achieved, 65
 and alcoholics, 61-75
 anxiety, 63
 baseline
 adequate, 73
 sensitive, 65-70
 stable, 65-69
 behavioral consequences, 72
 effort required to obtain, 63
 intake fluctuation, 65
 manipulation, experimental, 63-65
 beverage type, 64

- Ethanol (*cont.*)
 manipulation, experimental (*cont.*)
 isolation, 64, 67, 69, 71
 socialization, 64, 70
 odor as stimulus control, 24, 25
 as reinforcer, 13-15, 23
 restricted access, 71
 self-administration, 26-30
 isolation, 26, 27
 optional, 62, 63, 71
 socialization, 27
 stress, 26
 setting, 72
 stress, 26, 64
 Ethchlorvynol, 231
 Evaluation
 behavioral, 165, 166
 functional, 165, 166
 maturational, 165, 166
 postnatal, 165, 166
 Excitation and acetylcholine, 129-134
 Extrapyrarnidal symptom (EPS), 267, 268
- Fatigue, 182
 Fear-and-anxiety model, 281
 Fla-63, 140
 Flavor as conditioned cue, 6
 Flinch-jump method, 84, 85
 jump threshold, 86, 90
 Flurazepam, 273
 Foot shock, 84, 269, 270
 Forebrain bundle, medial, lesion, 84, 85, 90, 92
- Ganglion, neuronal
 cell degeneration, 183
 Go/no go trial, 289-292
- Hallucinogen, 231
 Haloperidol, 7, 24, 140, 267, 269, 271
 Hashish smoking by rhesus monkey, 15, 16
 Hedonal, 231
 Heroin, 28
 Hot-plate method for pain, 85
 5-HT, *see* Serotonin
 6-Hydroxydopamine, 109, 111, 112
 5-Hydroxyindolacetic acid, 125, 128
 5-Hydroxytryptamine, 125
 5-Hydroxytryptophan, 119-126
 Hyperkinesis, 182
 Hypesthesia, 220
- Imipramine, 15, 16, 139, 231, 270, 273
 Index of curvature, 252
 drug effect on, 252
- Interaction, maternal-fetal, 164
 Iproniazid, 119, 129, 131, 132
 Iraq
 methylmercury epidemic, 211
 Isotope pulse labeling, 98
- Kanamycin and deafness, 196, 198
- Latency, 164-165
 Lead, consequences
 behavioral, 158
 neurological, 158
 Levorphanol, 244
 Liver, fatty degeneration of, 183
d-Lysergic acid diethylamide (LSD), 97, 101,
 103-107
 Lysosome, giant, 174
- Macaca arctoides*, 216-220
Macaca irus, 197
Macaca nemestrina, 197
 Maintenance of behavior, 12
 Memory, 284-288
 decay process, 287
 drug effects, 208, 285
 stimulus, 285
 storage effects, 285, 288
 Meperidine, 244
 Meprobamate, 230, 231, 269
 Mercury
 and avoidance behavior, 210
 behavioral effect, 207-224
 in cat, 210
 consequences, behavioral, 158
 consequences, neurological, 158
 in felt-hat industry, 209
 in goldfish, 210
 inorganic, 208-210
 memory impairment, 208
 in pigeon, 209, 210
 in rat, 209, 210
 and sex, 210
 in thermometer factory, 208
 tremor, 208, 209
 vapor, inhaled, 208-210, 213
 Mercury chloride, ingested, 210
 Mescaline, 97, 99, 101-108
 Mesothelioma and asbestos, 155
 Metabolism defined, 138
 Metaraminol, 123, 126, 127
 Methadone, 30
 Methamphetamine, 18, 19, 22, 24, 139, 149,
 182, 183, 185, 188-190, 250
 behavioral effects, 185-190
 biochemistry, 190, 191

- Methamphetamine (*cont.*)
 chronic use, 185-191
 death, 185
 future research, 191, 192
 and morphology, 190, 191
 toxicity, 185
- Methanol, 195
- Methohexitol, 17
- Methylmercury, 167-175
 behavioral effects, 207-224
 in chicks, 213
 death, premature, 172, 174
 debilitation, 172, 174
 destruction of visual cortex, 215
 effect on offspring, 169, 170
 and hypesthesia, 220, 221
 in Iraq, 211
 lifetime findings, 174
 loss of peripheral vision, 215-220
 of visual cortex, 215
 in *Macaca arctoides*, 216-220
 motor effects, 220-222
 in mouse, 211
 neuromuscular evaluation, 171
 in pigeon, 210-214
 behavior, learned, 211, 212
 behavior, unlearned, 211, 212
 neurological signs, 211, 212
 prenatal exposure, 170
 in primate, 215-222
 hypesthesia, 220
 motor effects, 220-222
 visual effects, 215-220
 in rat, 212
 in spider, 212
 swimming performance, 171
- Methylmercury dicyandiamide, 168, 169
- Methylphenidate, 139
- α -Methyltryptamine, 231
- α -Methyl-*p*-tyrosine, 7, 18, 24, 87, 122, 126, 140, 141
- Minimal brain dysfunction, *see* Brain
- Molecular roulette, 79
- Monkey, 7, 242, 244; *see also* *Macaca*, Rhesus monkey, Squirrel monkey
- Monoamine oxidase inhibitor, 119, 120, 140
- Morphine, 15-18, 22, 24, 25, 92, 230, 231, 244, 271
 abstinence syndrome, 46
 in monkey, self-administration, 6
 in pigeon, 47
 as primary reinforcing agent, 6
 in rat, 4, 5
 in rhesus monkey, 46, 56-59
- Nalorphine, 6
- Naloxone, 24, 28, 46-49, 55-59
 avoidance, 55
 escape, 54, 55
 response to, 46-53
- Naltrexone, 28
- Narcolepsy, 182
- Narcotic antagonist, *see* Antagonist
- Nerve ending, drawing, 127
- Nerve-fiber myelination, incomplete, 174
- Neurochemistry and behavior, 77-81, 95-115
- Neuroleptics, 266-268
 and brain dopamine receptor, 267
- Neuron
 degeneration, 174
 model, 140
- Neurotransmitter, 118
 simultaneous occurrence in cyclic depression, 135
- Nicotine, 231
- Nitrazepam, 238
- Noise consequences
 behavioral, 158
 neurological, 158
- Noise pollution, 157
- Norepinephrine, 85-87, 96, 101, 104, 106, 109-113, 120, 123, 126, 139-142, 147, 148, 269, 278
- Normetanephrine, 110
- Obesity, 182
- Open-field test, 211
- Oxazepam, 231, 273
- Pain sensitivity, 87, 89
 hot-plate method, 85
 paw-licking latency, 85, 88, 89
- Panogen, *see* Methylmercury dicyandiamide
- Paw-licking latency, 85, 88, 89
- Pentobarbital, 5, 21, 29, 231-234, 237-240, 252
 and monkey, 6
 and rat, 6
- Perfusion method, 98
 of lateral ventricle, 98-103
 schedule, 98-113
- Perphenazine, 267
- Pharmacology, behavioral, *see* Behavioral pharmacology
- Pheniprazine
 and color blindness, 199, 200
 and depression, mental, 199
- Phenothiazine, 78, 79, 230, 231
- Phenylethylamine, 139
- Pigeon, 38, 46, 47, 79, 119-123, 126, 139, 199, 200, 233, 238, 239, 242-244, 250-257, 259, 270
- Placenta
 as barrier, 162, 163

- Placenta (*cont.*)
 and thalidomide, 163
- Pollutants, consequences (listed)
 behavioral, 158
 neurological, 158
- Polydypsia, schedule-induced, 6, 13, 14, 18
- Primary reinforcing agent, 4
 morphine as, 6
- Progressive ratio test, 5
- Promazine, 252, 253, 259, 269
- Propanediol, 242
- Propranolol, 231
- Psychiatry, biological, 77, 78
- Psychosis, theory of, 78
- Psychotropic agent, rate-dependent, 272
- Ptosis, 267, 268
- Punished responding, *see* Punishment
- Punishment
 codeine-reinforced, 49-53
 defined, 229
 drug effect on, 231-247
 those that increase responding, 231
 those that do not, 231
 those that increase and do not, 231
 duration, 232-234
 early work, 230
 intensity, 232-234
 rate-dependent, 237-241
 reinforcement, positive, 241, 242
 responding, 231-247
 drug effect on, 229-247
 schedule of presentation, 234-237
 by shock, electric, 230-232
 yoked procedure, 236
- Push-pull cannula method, 97
 with isotope pulse labeling, 98
 with perfusion, 98-101
- Pyrogallol, 140
- Quinine sulfate, 231
- Radiation as pollutant, 157
- Rat, 38, 120, 121, 126, 242, 244, 256, 258,
 270, 271, 273, 275, 278-280, 285-288,
 290
 morphine, imbibed, 4, 6
 morphine, injected, 4
 opiate drinkers, 7
 opiate nondrinkers, 7
 shaved, operating a heat lamp, 8
 working for morphine, 5
- Reinforcement, 12, 45, 46, 139, 188, 227
 codeine as, 49-53
 continuous, 242
 by drugs, 12, 23, 25
 of food schedule, 187-189
- Reinforcement (*cont.*)
 positive in punished responding, 241, 242
 and responding, 49-53
 schedule, 265-282
 concurrent, 273
 multiple, 273, 274
 schema, 187
- Reserpine, 77, 80, 92, 99, 139, 141, 231, 268
 pretreatment, 141
- Responding,
 abortive, 243
 increased, 288-291
 reinforced, 49-53
 punishment of, 49-53
- Rhesus monkey, 42, 43, 46, 56-59, 185, 186,
 200
 and chlordiazepoxide, 15
 and codeine, 49-53
 dark adaptation, 200, 204, 205
 and ethanol, 14
 and hashish, 14-16
 and morphine, 46, 47, 53, 56-59
 and secobarbital, 15
- Schedule of drug, 5-6
 -controlled behavior, 95-115, 225-227
 conditioning, 6, 7
 fixed-interval, 226
 fixed-ratio, 226
 ratio, 5
 variation, diurnal, 7
- Schizophrenia, 78
- Scopolamine, 231, 252-256, 259, 260, 285,
 286-293
- Secobarbital, 15, 29
- Sensory system
 color blindness due to drugs, 199
 deafness due to drugs, 196, 197
 psychophysical evaluation, 195-205
 toxic effects on, 195-205
- Serotonin, 80, 96, 118, 277
 depletion, 83-93
 and behavior, 83-93
 depression of approach behavior, 119-123
 mechanism proposed, 126-129
 diurnal rhythm in brain, 88
 and medial forebrain bundle, 84
- Shock, electric
 as negative reinforcer, 56
 response-contingent, 56-59
- Shuttle-box avoidance, 111
 acquisition, 111
- Sidman shock-avoidance schedule, 129, 267
- Signal detection analysis, 293
- Skinner's work, 156, 276
- Sodium thiopental, 92

- Spider-web construction
 - and methylmercury, 212
- Squirrel monkey, 38, 139, 196, 275, 277
 - and cocaine, 38-42
 - key-pressing, 39, 40
- Stabilimetric method, 85
- Stimulus
 - aversive
 - ambient temperature, 145
 - electric grid, shock, 145
 - electroconvulsive shock, 145
 - forced exercise, 144
 - immobilization, 144
 - fixed consecutive number, 253, 254, 260
 - fixed-interval, 250-254
 - fixed-ratio, 250, 251
 - and memory, 285
 - sensitivity to, 293
 - variable-interval, 259
- Streptomycin, 195
 - causing deafness, 195
- Suppression, conditioned, 236
- Synapse, cholinergic
 - simplified model, 134

- T-cell system, 175
- Tapidum lucidum bleaching by drug, 200-203, 205
- Teratology
 - behavioral, 163, 164
 - defined, 163
- Teratology (*cont.*)
 - experimental design, 167, 168
 - longitudinal, 167, 168
- Tetrabenazine, 129, 139, 268, 269
- Tetrahydrocannabinol, 16
- Thalidomide tragedy, 163
- Thioridazine, 267, 268
- Tolerance, behavioral, 186
- Toxicology
 - behavioral, 155-160
 - as subspecialty of pathology, 155
- Tranquilizer, major, *see* Amphetamine, Chlorpromazine, Morphine, Phenthiazine
- Tranquilizer, minor, *see* Barbiturate, Benzodiazepine, Meprobamate
- Trifluoperazine, 24, 267, 269
- Tryptamine antagonist, 231
- L-Tryptophan, 120, 121
- Tryptophan-5-hydroxylase, 91
- Tubule, renal, necrosis, 183
- Tyramine, 103
- Tyrosine hydroxylase inhibitor, 140

- Urea as extracellular marker, 97, 99, 100
- Urethane, 231

- Vision and mercury, 215-220

- Water reinforcement, 148